Propanolamines
Research News and Information

Sunday, November 22, 2009

The time course of dopamine transmission in the ventral tegmental area.

19 Oct 2009 Synaptic transmission mediated by G-protein coupled receptors (GPCR) is not generally thought to be point-to-point. To determine the extent over which dopamine signals in the midbrain, the present study examined the concentration and time course of ... Read more...

1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.

22 Sep 2009 Sequential structural modifications of the aryloxypropanamine template (e.g., atomoxetine, 2) led to a novel series of 1-(3-amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors (NRIs). ... Read more...

Dynamics of fast and slow inhibition from cerebellar golgi cells allow flexible control of synaptic integration.

22 Sep 2009 Throughout the brain, multiple interneuron types influence distinct aspects of synaptic processing. Interneuron diversity can thereby promote differential firing from neurons receiving common excitation. In contrast, Golgi cells are the sole ... Read more...

Latest indexed articles for 'Propanolamines'

These are the very latest articles for this heading:

• The time course of dopamine transmission in the ventral tegmental area. 19 Oct 2009
• 1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors. 22 Sep 2009
• Dynamics of fast and slow inhibition from cerebellar golgi cells allow flexible control of synaptic integration. 22 Sep 2009
• GABA(B) receptor activation triggers BDNF release and promotes the maturation of GABAergic synapses. 14 Sep 2009
• The timing of external input controls the sign of plasticity at local synapses. 4 Sep 2009
• Electroconvulsive therapy in the setting of implantable cardioverter-defibrillators. 30 Aug 2009
• Beta-blockers for hypertension: are they going out of style? 30 Aug 2009
• Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers. 30 Aug 2009
• Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. 30 Aug 2009
• The effectiveness of collaborative medicine reviews in delaying time to next hospitalization for patients with heart failure in the practice setting: results of a cohort study. 17 Aug 2009
• Linking genetically defined neurons to behavior through a broadly applicable silencing allele. 11 Aug 2009
• Ligand entry and exit pathways in the beta2-adrenergic receptor. 4 Aug 2009
• Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial. 30 Jul 2009
• Found in translation: metoprolol improves survival more than carvedilol in a mouse model of inherited dilated cardiomyopathy. 29 Jul 2009
• Effect and mechanism of esmolol given during cardiopulmonary resuscitation in a porcine ventricular fibrillation model. 3 Jul 2009
• Evaluation of beta1L-adrenoceptors in rabbit heart by tissue segment binding assay. Jul 2009
• Acute cold exposure-induced down-regulation of CIDEA, cell death-inducing DNA fragmentation factor-alpha-like effector A, in rat interscapular brown adipose tissue by sympathetically activated beta3-adrenoreceptors. Jul 2009
• Occupational airborne contact dermatitis to simvastatin, carvedilol, and zolpidem. 29 Jun 2009
• Realities of newer beta-blockers for the management of hypertension. 29 Jun 2009
• [B-type natriuretic peptide (BNP) levels and the effects of carvedilol on BNP levels in juvenile rats with right heart failure] 29 Jun 2009

See a longer list of these articles.

Technical information about 'Propanolamines'

Definition: AMINO ALCOHOLS containing the propanolamine (NH2CH2CHOHCH2) group and its derivatives.

Registry Number: 0

Descriptor UI: D011412

Alternative terms: Propanolamines; Aminopropanols;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D02.033.100.624; D02.033.755.624; D02.092.063.624;

History Note: 74